Endocrinology

Supportive Care

Questions discussed in this category

In SIADH due to malignancy, do you prefer to use free water restriction or salt tablets?

Or other therapy - e.g., tolvaptan? Free water restriction may hinder QOL. Salt tablets may raise levels more quickly but have risks of edema and hype...

1 Answer available

Are there any concerns regarding side effects in changing from denosumab to zolendronic acid or vice versa?

1 Answer available

For patients on a bone-modifying agent for osteoporosis/severe osteopenia in the context of adjuvant AI therapy, how do you manage the bone-modifying agent once their AI course is complete?

1 Answer available

For patients with cancer receiving a bone-modifying agent (bisphosphonate or denosumab) who suffer a fracture requiring stabilization or reconstruction, how do you manage the bone-modifying agent peri-operatively?

Is there concern for impaired healing? Do you pause therapy and for how long?

1 Answer available

Papers discussed in this category

J Clin Oncol, 2019 Sep 18

Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline.

Cancer Chemother Pharmacol, 2021 Mar 31

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.

J Bone Miner Metab, 2020 Jul 12

Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.

Endocrinology

Supportive Care

Questions discussed in this category

Papers discussed in this category

Related Topics in Endocrinology